Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Acuity Says Primate Data on RNAi Drug Positive, Schedules Meeting with FDA

Acuity Says Primate Data on RNAi Drug Positive, Schedules Meeting with FDA

Nov 14, 2003
Premium

Acuity Pharmaceuticals said this week that data from a recently completed primate study of Cand5, its RNAi treatment for age-related macular degeneration, indicate that the drug is both safe and effective.

The company has also scheduled a meeting with US regulators to discuss the details of filing an investigational new drug application for Cand5, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

What's Popular?

In Gene Silencing/Gene Editing

  1. ERS Genomics Licenses CRISPR Patents to Otsuka Pharmaceutical

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.